Overview

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Status:
Active, not recruiting

Trial end date:
2021-09-02

Target enrollment:

Participant gender:

Summary

This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

MedImmune LLC

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab